Renal biomarker changes associated with hyaline droplet nephropathy in rats are time and potentially compound dependent.

Brott DA, Bentley P, Nadella MV, Thurman D, Fikes J, Cheatham L, McGrath F, Luo W, Kinter LB.
Journal   Toxicology
Species  
Analytes Measured   Albumin , Clusterin , HAVCR1 KIM-1 , Osteopontin , RPA-1
Matrix Tested   Urine
Year   2012
Volume  
Page Numbers  
Application   Kidney Injury , Toxicology
Abstract
Alpha 2µ-globulin mediated hyaline droplet nephropathy (HDN) is a male rat specific lesion induced when a compound or metabolite binds to alpha 2µ-globulin. The objective of this study was to investigate if the newer and more sensitive renal biomarkers would be altered with HDN as well as be able to distinguish between HDN and oxidative stress-induced kidney injury. Rats were dosed orally for 7 days to determine (1) if HDN (induced by 2-propanol or d-limonene) altered the newer renal biomarkers and not BUN or creatinine, (2) if renal biomarkers could distinguish between HDN and oxidative stress-induced kidney injury (potassium bromate), (3) sensitivity of HDN-induced renal biomarker changes relative to d-limonene dose, and (4) reversibility of HDN and renal biomarkers, using vehicle or 300mg/kg/day d-limonene with 7 days of dosing and necropsies scheduled over the period of Days 8-85. HDN-induced renal biomarker changes in male rats were potentially compound specific: (1) 2-propanol induced mild HDN without increased renal biomarkers, (2) potassium bromate induced moderate HDN with increased clusterin, and (3) d-limonene induced marked HDN with increased αGST, µGST and albumin. Administration of potassium bromate did not result in oxidative stress-induced kidney injury, based on histopathology and renal biomarkers creatinine and BUN. The compound d-limonene induced a dose dependent increase in HDN severity and renal biomarker changes without altering BUN, creatinine or NAG: (1) minimal induction of HDN and no altered biomarkers at 10mg/kg/day, (2) mild induction of HDN with increased αGST and µGST at 50mg/kg/day and (3) marked induction of HDN with increased αGST, µGST and albumin at 300mg/kg/day. HDN induced by d-limonene was reversible, but with a variable renal biomarker pattern over time: Day 8 there was increased αGST, µGST and albumin; on Day 15 increased clusterin, albumin and Kim-1. In summary, HDN altered the newer and more sensitive renal biomarkers in a time and possibly compound dependent manner.

View Publications

Related Products

U-PLEX Human HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Human
U-PLEX Human HAVCR1/KIM-1 Assay, 384-well
HAVCR1/KIM-1 | Human
Singleplex
U-PLEX Human HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Human
Singleplex
R-PLEX Mouse HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Mouse
R-PLEX Mouse HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Mouse
Singleplex
U-PLEX Human Clusterin 384-Well Assay
Clusterin | Human
Singleplex
U-PLEX Custom Biomarker Group 3 (human) 384-well Assays
Human
Multiplex
U-PLEX Custom Biomarker Group 3 (human) Assays
Human
Multiplex
U-PLEX Human Clusterin Antibody Set
Clusterin | Human
U-PLEX Metabolic Combo 2 (human)
Adiponectin, ApoA1, ApoC3, Clusterin, CRP, DPPIV, NGAL/LCN2, RBP4, SHBG, sTfR-1 | Human
Multiplex
U-PLEX Kidney Injury Combo 1 (human)
A2M, Clusterin, Cystatin C, NGAL/LCN2, RBP4, Serpin A1 | Human
Multiplex
U-PLEX Human Clusterin Assay
Clusterin | Human
Singleplex
R-PLEX Rat Albumin Antibody Set
Albumin | Rat
R-PLEX Human Albumin Assay
Albumin | Human
Singleplex
R-PLEX Rat Osteopontin Assay
Osteopontin | Rat
Singleplex
R-PLEX Rat Albumin Assay
Albumin | Rat
Singleplex
R-PLEX Mouse Clusterin Assay
Clusterin | Mouse
Singleplex
R-PLEX Human Osteopontin Assay
Osteopontin | Human
Singleplex
R-PLEX Rat HAVCR1/KIM-1 Assay
HAVCR1/KIM-1 | Rat
Singleplex
R-PLEX Mouse Clusterin Antibody Set
Clusterin | Mouse
R-PLEX Human Albumin Antibody Set
Albumin | Human
R-PLEX Rat Osteopontin Antibody Set
Osteopontin | Rat
R-PLEX Rat HAVCR1/KIM-1 Antibody Set
HAVCR1/KIM-1 | Rat
R-PLEX Human Osteopontin Antibody Set
Osteopontin | Human
Kidney Injury Panel 3 Human Kit
Calbindin, Clusterin, HAVCR1/KIM-1, Osteoactivin, TFF3, VEGF-A | Human
Multiplex
Rat Clusterin Kit
Clusterin | Rat
Singleplex
Kidney Injury Panel 1 Rat Kit
Albumin, HAVCR1/KIM-1, NGAL/LCN2, Osteopontin | Rat
Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays
APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 | Human
Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays
APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 | Human
Multiplex
U-PLEX Immuno-Oncology Group 1 (human) 384-well Assays
BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF (basic), FLT3L, Fractalkine, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L2, PlGF, RANKL/TNFSF11, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, YKL-40 | Human
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters